January is Love Your Liver Month 💚 – but how can you best care for this vital organ?
It’s not just about cutting alcohol consumption, says Lara Campana, Resolution Therapeutics‘ SVP of Research and Translational Science and scientific co-founder.
Liver disease is an area of critical unmet medical need. In the UK, cases of liver disease and life-threatening end-stage liver disease (ESLD) continue to increase rapidly, and in the US, ESLD contributes to over 50,000 deaths every year.
With no approved medical therapies for end-stage liver disease, liver transplant is currently the only option for patients, but it is limited by donor availability and complexity of the surgery.
At Resolution, we are committed to transforming the treatment landscape for this terrible disease, and bringing new hope to patients. Our lead candidate RTX001, an engineered regenerative macrophage therapy, is currently being evaluated in the EMERALD Phase I/II study in patients with a history of decompensated liver cirrhosis, with enrolment currently ongoing in the UK and Spain.
🎥 Watch the video above to learn more about how we are working to address this critical unmet need.